Compare HROW & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HROW | TSLX |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | 373 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 2011 |
| Metric | HROW | TSLX |
|---|---|---|
| Price | $42.21 | $16.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $69.86 | $21.61 |
| AVG Volume (30 Days) | ★ 752.2K | 629.6K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.82% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.62 | N/A |
| Revenue Next Year | $50.77 | $1.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.54 | $16.37 |
| 52 Week High | $54.98 | $25.17 |
| Indicator | HROW | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 71.20 | 35.28 |
| Support Level | $40.61 | N/A |
| Resistance Level | $51.01 | $18.65 |
| Average True Range (ATR) | 2.10 | 0.41 |
| MACD | 1.07 | -0.06 |
| Stochastic Oscillator | 96.39 | 3.43 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.